Atorvastatin API Market - Top Companies and Manufacturers

Companies Dominating the Atorvastatin API Landscape

The need for niche competencies for manufacturing APIs has encouraged pharma companies to outsource production activities rather than manufacturing them in their own facilities. During the foreseeable years, this factor is expected to provide lucrative growth opportunities to key players in the atorvastatin API market. For instance, in August 2023, Merck & Co. established MK-0616 which is the oral PCSK9 inhibitor used in adults. It completed clinical trials in the year 2023 and was presented at scientific conferences including the 72nd Annual Session coupled with the World Congress of Cardiology at the American College of Cardiology. Here's the list of some key players:

Centrient Pharmaceuticals
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Morepen Laboratories Ltd.
Dr. Reddy’s Laboratories Ltd.
Anuh Pharma Ltd.
Jubilant Life Sciences Ltd.
Ind-Swift Labs Ltd.
Zhejiang Hisun Pharmaceutical Co Ltd.
Cadila Pharmaceuticals

Browse Key Market Insights with Data Illustration:

Atorvastatin API Market Size & Share, Growth Report 2037

In the News

In March 2024, Camber Pharmaceuticals announced the addition of atorvastatin calcium tablets, USP to its lineup. These tablets come in 90, 500, and 1000-count bottles containing 10 mg.
In June 2023, CMP Pharma, Inc. declared that Atorvaliq (atorvastatin calcium) Oral Suspension, 20 mg/5 mL was the first and only FDA-approved oral liquid of atorvastatin. With this, high cholesterol and specific risk factors for heart disease or stroke can be treated.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the atorvastatin API market was over USD 1.7 billion.

The market size for the atorvastatin API market is projected to reach USD 3.5 billion by the end of 2037 expanding at a CAGR of 6.3% during the forecast period i.e., between 2025-2037.

The major players in the market are Dr. Reddy’s Laboratories Ltd., Anuh Pharma Ltd., Jubilant Life Sciences Ltd., Ind-Swift Labs Ltd., Zhejiang Hisun Pharmaceutical Co Ltd., Cadila Pharmaceuticals, and more.

In terms of application, the hypercholesterolemia segment is anticipated to garner the largest market share of 82.8% by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to account for a prominent share of 62.8% by the end of 2037 and provide more business opportunities in the future.

Atorvastatin API Market - Top Companies and Manufacturers

Companies Dominating the Atorvastatin API Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the atorvastatin API market?

What is the outlook for the atorvastatin API market?

Who are the major players dominating the atorvastatin API market?

Which segment will capture the significant market share for the atorvastatin API market by 2037?

Which region will provide more business opportunities for the growth of the atorvastatin API market in the future?